^Reddy GK, Gralla RJ, Hesketh PJ (April 2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive Cancer Therapy. 3 (3): 140–2.
doi:
10.3816/SCT.2006.n.011.
PMID18632487.
^Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, et al. (October 2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European Neuropsychopharmacology. 18 (10): 729–50.
doi:
10.1016/j.euroneuro.2008.06.002.
PMID18657401.
S2CID8258896.
^Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at
ClinicalTrials.gov